XTRA:AFX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Carl Zeiss Meditec

Executive Summary

Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally.


Snowflake Analysis

Flawless balance sheet with solid track record.


Similar Companies

Share Price & News

How has Carl Zeiss Meditec's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AFX has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

6.6%

AFX

0.9%

DE Medical Equipment

2.1%

DE Market


1 Year Return

7.3%

AFX

20.3%

DE Medical Equipment

2.1%

DE Market

Return vs Industry: AFX underperformed the German Medical Equipment industry which returned 20.4% over the past year.

Return vs Market: AFX exceeded the German Market which returned 3% over the past year.


Shareholder returns

AFXIndustryMarket
7 Day6.6%0.9%2.1%
30 Day-0.7%-2.8%-0.8%
90 Day0.3%15.1%20.1%
1 Year7.3%7.3%21.8%20.3%4.2%2.1%
3 Year113.0%109.3%121.8%117.1%3.7%-4.7%
5 Year291.9%276.6%248.4%234.4%10.7%-4.0%

Price Volatility Vs. Market

How volatile is Carl Zeiss Meditec's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Carl Zeiss Meditec undervalued compared to its fair value and its price relative to the market?

50.15x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: AFX (€92.5) is trading above our estimate of fair value (€61.38)

Significantly Below Fair Value: AFX is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: AFX is good value based on its PE Ratio (50.1x) compared to the Medical Equipment industry average (53x).

PE vs Market: AFX is poor value based on its PE Ratio (50.1x) compared to the German market (21.1x).


Price to Earnings Growth Ratio

PEG Ratio: AFX is poor value based on its PEG Ratio (3.4x)


Price to Book Ratio

PB vs Industry: AFX is overvalued based on its PB Ratio (5.7x) compared to the DE Medical Equipment industry average (4.5x).


Next Steps

Future Growth

How is Carl Zeiss Meditec forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

14.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AFX's forecast earnings growth (14.7% per year) is above the savings rate (0.2%).

Earnings vs Market: AFX's earnings (14.7% per year) are forecast to grow slower than the German market (22.4% per year).

High Growth Earnings: AFX's earnings are forecast to grow, but not significantly.

Revenue vs Market: AFX's revenue (8.1% per year) is forecast to grow faster than the German market (5.9% per year).

High Growth Revenue: AFX's revenue (8.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AFX's Return on Equity is forecast to be low in 3 years time (14%).


Next Steps

Past Performance

How has Carl Zeiss Meditec performed over the past 5 years?

18.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AFX has high quality earnings.

Growing Profit Margin: AFX's current net profit margins (11%) are higher than last year (9.6%).


Past Earnings Growth Analysis

Earnings Trend: AFX's earnings have grown by 18.3% per year over the past 5 years.

Accelerating Growth: AFX's earnings growth over the past year (28.6%) exceeds its 5-year average (18.3% per year).

Earnings vs Industry: AFX earnings growth over the past year (28.6%) exceeded the Medical Equipment industry 8.2%.


Return on Equity

High ROE: AFX's Return on Equity (11.3%) is considered low.


Next Steps

Financial Health

How is Carl Zeiss Meditec's financial position?


Financial Position Analysis

Short Term Liabilities: AFX's short term assets (€1.4B) exceed its short term liabilities (€335.4M).

Long Term Liabilities: AFX's short term assets (€1.4B) exceed its long term liabilities (€265.7M).


Debt to Equity History and Analysis

Debt Level: AFX is debt free.

Reducing Debt: AFX has no debt compared to 5 years ago when its debt to equity ratio was 0.6%.

Debt Coverage: AFX has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: AFX has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Carl Zeiss Meditec current dividend yield, its reliability and sustainability?

0.70%

Current Dividend Yield


Upcoming Dividend Payment


Dividend Yield vs Market

Notable Dividend: AFX's dividend (0.7%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.26%).

High Dividend: AFX's dividend (0.7%) is low compared to the top 25% of dividend payers in the German market (3.8%).


Stability and Growth of Payments

Stable Dividend: AFX is not paying a notable dividend for the German market, therefore no need to check if payments are stable.

Growing Dividend: AFX is not paying a notable dividend for the German market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: AFX is not paying a notable dividend for the German market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AFX's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Ludwin Monz (57yo)

10.33yrs

Tenure

€1,853,900

Compensation

Dr. Ludwin Monz, Ph.D., M.B.A. has been the Chairman of Management Board at Carl Zeiss Meditec AG since October 8, 2007. Dr. Monz has been the Chief Executive Officer and President of Carl Zeiss Meditec AG ...


CEO Compensation Analysis

Compensation vs Market: Ludwin's total compensation ($USD2.09M) is below average for companies of similar size in the German market ($USD3.54M).

Compensation vs Earnings: Ludwin's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Ludwin Monz
President10.33yrs€1.85mno data
Justus Wehmer
CFO & Member of the Management Board1.75yrs€855.50kno data
Jan de Cler
Head of Surgical Ophthalmology & Member of Management Board1.75yrs€921.70kno data
Sebastian Frericks
Director of Investor Relationsno datano datano data
Martin Wiechmann
Head of the Planetarium Business Unitno datano datano data
Mike Wang
Head of Marketing - Shanghaino datano datano data
Steven Schallhorn
Chief Medical Officer for Global Ophthalmic Devices3.75yrsno datano data
Andrew Chang
Head of Sales for Ophthalmic Devices & President of Carl Zeiss Meditecno datano datano data
Laurie Ferguson
Head of Global Communications Ophthalmic Devicesno datano datano data
Euan Thomson
President of Ophthalmic Devices & Head of the Ophthalmic Devices Strategic Business Unit0.17yrno datano data

1.8yrs

Average Tenure

57yo

Average Age

Experienced Management: AFX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Michael Kaschke
Chairman of Supervisory Board10.33yrs€64.00kno data
Markus Guthoff
Member of the Supervisory Board15.75yrs€56.00kno data
Christian Müller
Supervisory Board Member1.33yrs€23.80kno data
Cornelia Grandy
Employee Representative Member of Supervisory Board8.75yrs€32.00kno data
Tania von der Goltz
Deputy Chairwoman of the Supervisory Board2.25yrs€48.00kno data
René Denner
Member of Supervisory Board0.75yrno datano data

5.5yrs

Average Tenure

53yo

Average Age

Experienced Board: AFX's board of directors are considered experienced (5.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Carl Zeiss Meditec AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Carl Zeiss Meditec AG
  • Ticker: AFX
  • Exchange: XTRA
  • Founded: 2002
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €8.390b
  • Shares outstanding: 89.44m
  • Website: https://www.zeiss.com/meditec-ag/home.html

Number of Employees


Location

  • Carl Zeiss Meditec AG
  • Goschwitzer Strasse 51-52
  • Jena
  • Thuringia
  • 7745
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AFXDB (Deutsche Boerse AG)YesBearer SharesDEEURMar 2000
AFXXTRA (XETRA Trading Platform)YesBearer SharesDEEURMar 2000
0DHCLSE (London Stock Exchange)YesBearer SharesGBEURMar 2000
CZMW.FOTCPK (Pink Sheets LLC)YesBearer SharesUSUSDMar 2000
AFXDBATS-CHIXE (BATS 'Chi-X Europe')YesBearer SharesGBEURMar 2000
AFXSWX (SIX Swiss Exchange)YesBearer SharesCHCHFMar 2000
AFXWBAG (Wiener Boerse AG)YesBearer SharesATEURMar 2000
AFXETLX (Eurotlx)YesBearer SharesITEURMar 2000
CZMW.YOTCPK (Pink Sheets LLC)UNSPONSORED ADRUSUSDOct 2007
AFXADB (Deutsche Boerse AG)UNSPONSORED ADRDEEUROct 2007

Biography

Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery. This segment also offers optical coherence tomography devices, perimeters, fundus cameras, slit lamps, and therapeutic and refractive lasers for the diagnosis and treatment of various eye diseases, such as refraction, glaucoma, and other retinal diseases, as well as FORUM, an eye care data management system. The Microsurgery segment provides surgical microscopes and visualization solutions for neuro, spinal, dental, and plastic and reconstructive surgeries, as well as for ear, nose, and throat surgery; products for surgical treatment of tumors or vascular diseases, such as aneurysms; and INTRABEAM, a intraoperative radiotherapy device. Carl Zeiss Meditec AG serves ophthalmologists and optometrists, as well as physicians and surgeons in hospitals and outpatient surgery centers. The company was founded in 2002 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/07 20:50
End of Day Share Price2020/07/07 00:00
Earnings2020/03/31
Annual Earnings2019/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.